文档介绍：实用药物与临床 2022 年第 25 卷第 4 期 Practical Pharmacy And Clinical Remedies ,2022, Vol. 25 ,No. 4 cators and time ( 3
months ,6 months, 1 year, or 2 years) are selected for different response standards, which are also adapt to different ob­
jects ,then the scope of clinical application is improved. Recently, ALP and TBIL tend to be the main response indica­
tors ,and the time is mostly 1 year. It is applicable to non-cirrhotic patients. This paper reviews the different response
criteria of PBC for clinical reference and individualized treatment. This article reviews the different response standards
of PBC for clinical reference and individualized treatment.
Key words: Primary biliary cholangitis ； Ursodeoxycholic acid ； Biochemical response
0引言 白蛋白(Albumin, Alb)［5］。PBC 早期(1 、2 期)治
疗应答反应多数良好，部分早期、小于45岁、男性
从原发性胆汁性肝硬化(Primary biliary cir­
或晚期(3、4期)的PBC患者，治疗应答滞后或不
rhosis, PBC) 命名，再到2015 年更名为原发性胆汁
完全应答［6-8］。约35% ~40%的PBC患者对UD­
性胆管炎(Primary biliary cholangitis,PBC)历时60